Loading stock data…
Inovio Pharmaceuticals (INO)
$1.42-0.01 (-0.70%)
Market ClosedLast close Sep 8
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inovio Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.42 with a market capitalization of $90M. Wall Street consensus targets $3.17 (3 analysts), implying a +123.0% move over the next 12 months. The stock is currently 50% below its 52-week high of $2.82, remaining 0.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +123.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $65,343 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.95M↓ | -$17.48M↑ | -$21.21M↑ | -$23.08M↑ | -$25.05M |
| Net Income | -$19.68M↓ | $3.76M↑ | -$45.50M↓ | -$23.52M↓ | -$19.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$90.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1399.73%
Volume
Today's trading volume
3.46M
Recent News
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
Inovio reports a narrowed net loss and strong progress toward a potential INO-3107 launch, while securing funding through late Q1 2027.
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call
Inovio Pharmaceuticals Q2 Earnings Call Highlights
Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31,
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial
The study showed that the treatment helped reverse precancerous changes in the cervix and clear the high-risk HPV virus that causes them in many patients.